- Home
- BOLD vs BNR Comparison
BOLD vs BNR Comparison
Compare BOLD & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- BNR
- Stock Information
- Founded
- BOLD 2018
- BNR 2014
- Country
- BOLD United States
- BNR China
- Employees
- BOLD N/A
- BNR N/A
- Industry
- BOLD
- BNR Medical Specialities
- Sector
- BOLD
- BNR Health Care
- Exchange
- BOLD Nasdaq
- BNR Nasdaq
- Market Cap
- BOLD 30.3M
- BNR 29.1M
- IPO Year
- BOLD 2024
- BNR 2020
- Fundamental
- Price
- BOLD $1.44
- BNR $2.33
- Analyst Decision
- BOLD Hold
- BNR
- Analyst Count
- BOLD 1
- BNR 0
- Target Price
- BOLD N/A
- BNR N/A
- AVG Volume (30 Days)
- BOLD 61.2K
- BNR 53.9K
- Earning Date
- BOLD 05-09-2025
- BNR 05-28-2025
- Dividend Yield
- BOLD N/A
- BNR N/A
- EPS Growth
- BOLD N/A
- BNR N/A
- EPS
- BOLD N/A
- BNR N/A
- Revenue
- BOLD N/A
- BNR $70,669,261.00
- Revenue This Year
- BOLD N/A
- BNR $136.32
- Revenue Next Year
- BOLD N/A
- BNR N/A
- P/E Ratio
- BOLD N/A
- BNR N/A
- Revenue Growth
- BOLD N/A
- BNR N/A
- 52 Week Low
- BOLD $1.06
- BNR $2.18
- 52 Week High
- BOLD $12.26
- BNR $8.99
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- BNR 22.82
- Support Level
- BOLD N/A
- BNR $2.30
- Resistance Level
- BOLD N/A
- BNR $2.78
- Average True Range (ATR)
- BOLD 0.00
- BNR 0.29
- MACD
- BOLD 0.00
- BNR 0.03
- Stochastic Oscillator
- BOLD 0.00
- BNR 11.15
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.